An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND

Trial Profile

An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Malignant melanoma; Ovarian cancer; Pancreatic cancer; Sarcoma
  • Focus Therapeutic Use
  • Acronyms RESOUND
  • Most Recent Events

    • 11 Oct 2016 Results (n=20) from pancreatic cohort of the study presented at the 41st European Society for Medical Oncology Congress.
    • 20 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top